Activity cliffs were systematically extracted from public domain X-ray structures of targets for which complexes with multiple ligands were available, following the concept of three-dimensional (3D) cliffs. Binding modes of ligands with well-defined potency measurements were compared in a pairwise manner, and their 3D similarity was calculated using a previously reported property density function-based method taking conformational, positional, and chemical differences into account. Requiring the presence of at least 80% 3D similarity and a potency difference of at least 2 orders of magnitude as cliff criteria, a total of 216 well-defined 3D activity cliffs were detected in the Protein Data Bank (PDB). These 3D-cliffs involved a total of 269 ligands active against 38 different targets belonging to 17 protein families. For 255 of these compounds, binding modes were available at high crystallographic resolution. All 3D-cliffs were analyzed in detail and assigned to different categories on the basis of crystallographic interaction patterns. In many instances, differences in ligand-target interactions suggested plausible causes for origins of 3D-cliffs. In other cases, short-range interactions seen in X-ray structures were insufficient to deduce possible reasons for cliff formation. The 3D-cliffs described herein further advance the rationalization of activity cliffs at the level of ligand-target interactions and should also be useful for other applications such as the calibration of energy functions for structure-based design. The pool of identified activity cliffs is provided to enable subsequent structure-based analyses of cliffs.
Publicly available kinase inhibitors have been analyzed in detail. Nearly 19000 inhibitors have been identified with activity against 266 different kinases. Thus, about half of the human kinome is currently covered with active small molecules. The distribution of inhibitors across the kinome is uneven. Most available kinase inhibitors are likely to be type I inhibitors. By contrast, type II inhibitors are rare but usually have high potency. Kinase inhibitors generally display high scaffold diversity. Activity cliffs with an at least 100-fold difference in potency are only found for inhibitors of 106 kinases, which is partly due to only small numbers of compounds available for many kinases, in addition to scaffold diversity. Moreover, kinase inhibitors are less promiscuous than often thought. More than 70% of available inhibitors are only annotated with a single kinase activity, and only ∼1% of the inhibitors are active against five or more kinases.
Using the example of cathepsin K, we demonstrate the design of highly potent and selective azadipeptide nitrile inhibitors. A systematic scan with respect to P2 and P3 substituents was carried out. Structural modifications strongly affected the enzyme-inhibitor association (but not dissociation) rate. A combination of optimized P2 and P3 substituents with a methylation of the P3-P2 amide linker resulted in the picomolar cathepsin K inhibitor 19 with remarkable selectivity over cathepsins L, B, and S.
A coumarin-tetrahydroquinoline hydride 8 was synthesized as a chemical tool for fluorescent labeling. The rigidified tricyclic coumarin structure was chosen for its suitable fluorescence properties. The connection of 8 with a vinyl sulfone building block was accomplished by convergent synthesis thereby leading to the coumarin-based, tripeptidomimetic activity-based probe 10, containing a Gly-Phe-Gly motif. Probe 10 was evaluated as inactivator of the therapeutically relevant human cysteine cathepsins S, L, K, and B: it showed particularly strong inactivation of cathepsin S. The detection of recombinant and native cathepsin S was demonstrated by applying 10 to in-gel fluorescence imaging.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.